The clinical features and outcomes in 21 patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma
10.3760/cma.j.issn.0578-1426.2012.10.013
- VernacularTitle:眼附属器黏膜相关淋巴样组织结外边缘区B细胞淋巴瘤21例临床特征及疗效分析
- Author:
Feng NING
;
Jin YE
;
Liqiang WEI
;
Xin LI
;
Jingwen WANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,mucosa-associated lymphoid tissue;
Therapy;
Prognosis;
Ocular adnexa
- From:
Chinese Journal of Internal Medicine
2012;51(10):784-787
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical features,therapies and prognosis in patients with mucosa-assoeiated lymphoid tissue (MALT) lymphoma in ocular adnexal marginal zone (OAML).Methods A retrospective analysis was made upon clinical data from 21 patients with OAML admitted into Beijing Tongren Hospital from June,2008 to December,2011.Results There were 12 (57.1 ％) men and 9(42.9％) women,with a median age of 57 (23-79) years old.Majority of patients had localized pathological changes.Among them,16 patients (76.2％) were in stage Ⅰ E,and 5 (23.8％) in stage Ⅳ E.Surgical resection as the sole treatment was performed in 13 patients (61.9％),and positron emission tomography CT(PET-CT) imaging demonstrated normal fluorine 18-fluorodeoxyglucose (FDG) uptake after surgical resection,who were managed with no further therapy.All the 13 patients were followed up for median 14 (5-38) months,and all in complete remission.Combination chemotherapy was given to 8(38.1％) patients.Three patients in stage Ⅰ E treated with COP (cyclophosphamide,vineristine and prednisone) or CHOP (cyclophosphamide,adriamycin,vincristine and prednisone) were all in partial remission.Five patients in stage ⅣE were treated with COP/CHOP in combination with rituximab,and all in complete remission.The 3-year overall survival rate and disease-free survival rate in the total patients were 100.0％ and 74.9％ respectively.Conclusions The patients with OAML generally have localized disease,show indolent clinical course,and present low lymphoma-related mortality.Surgical resection is a very important treatment in the patients with local disease.Systemic chemotherapy should be considered in patients at advanced stages.Rituximab in combination with chemotherapy can improve the remission rate.
